Plain-English translation of NCT07108998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called , given as an injection under the skin, can help patients with chronic lymphocytic leukemia or small lymphocytic lymphoma achieve deeper remissions after they've already responded to standard drug therapy. You would receive up to 12 cycles of this medication while continuing your current daily cancer pill. The goal is to see if the treatment can help your body eliminate any remaining cancer cells and allow you to eventually stop treatment altogether.
Many patients with these blood cancers respond well to their initial treatment but still have small amounts of cancer remaining that could come back. This medication is designed to work differently than standard drugs, potentially helping your immune system find and destroy any leftover cancer cells and achieve a deeper, longer-lasting remission.
You likely qualify if…
You likely don't qualify if…
You would continue taking your current daily cancer pill and receive injections of the new medication under your skin on a schedule that changes over time—starting with weekly injections during the first cycle, then tapering to less frequent injections over 12 cycles (about one year). Throughout the study, you would have blood tests, imaging scans, and possibly a bone marrow biopsy to check how well the treatment is working and whether remaining cancer cells have been eliminated. The trial will carefully monitor your safety and adjust your treatment plan based on how you respond.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Zulfa Omer
Collaborators
Genmab
Enrollment target
~22 participants
Started
August 2025
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
UCCC Clinical Trials Office
Zulfa Omer
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.